Clinical TrialApr 14, 2026, 08:31 AM
RenovoRx TAMP Therapy Shows Promising Pancreatic Cancer Data
AI Summary
RenovoRx announced positive clinical data for its TAMP (Trans-Arterial Micro-Perfusion) therapy platform in locally advanced pancreatic cancer (LAPC), presented at the 2026 SIR Annual Scientific Meeting. The data indicated TAMP is a promising approach for localized chemotherapy delivery, showing reduced systemic toxicity and notable reductions in tumor activity via metabolic imaging. These findings suggest a potential treatment response and may complement the company's ongoing Phase III TIGeR-PaC clinical trial.
Key Highlights
- TAMP therapy shows promise for local gemcitabine delivery in locally advanced pancreatic cancer (LAPC).
- Metabolic imaging (PET/CT) revealed notable reduction in tumor activity, suggesting treatment response.
- Treatment involved 8 cycles of intra-arterial chemotherapy administered over 2 months.
- TAMP aims to increase local drug concentration near the tumor while reducing systemic toxicity.
- Findings may complement RenovoRx's ongoing Phase III TIGeR-PaC clinical trial.
Price Impact
More from RNXT